Stempeutics, a leading Stem Cell Company, launches its second state-of-the-art Stem Cell Lab at Manipal University Campus
Released on: July 12, 2008, 12:06 am
Press Release Author: Brand-Comm
Industry: Healthcare
Press Release Summary: Stempeutics Research Pvt. Ltd, a Bangalore based Stem Cell Company is expanding its footprints both nationally and internationally. Stempeutics today inaugurated its second Stem Cell research & therapeutics facility at the Manipal University campus.
Press Release Body: . Facility will be used for advanced stem cell research in human embryonic stem cells in collaboration with Manipal Assisted Reproduction Center . Plans for establishing large scale production of Mesenchymal Stem Cells for Clinical Trials using innovative upscaling process . Plans to conduct pilot studies to address the needs of patients suffering with critical diseases like Dilated Cardio Myopathy, End Stage Liver Disease and Osteoarthritis Bangalore, July 11th 2008 - Stempeutics Research Pvt. Ltd, a Bangalore based Stem Cell Company is expanding its footprints both nationally and internationally. Stempeutics today inaugurated its second Stem Cell research & therapeutics facility at the Manipal University campus. Supported by University, the state-of-the-art facility located at Shirdi Sai Baba Cancer Hospital is conceived to further leverage the research & clinical experience gained and also to address the needs of patients with limited treatment options for the conditions like Dilated Cardio Myopathy, End Stage Lever Disease and Osteoarthritis. First Lab was established in Bangalore in 2006. Stempeutics manufacturing facility at Manipal is cGMP (current Good Manufacturing Practice) compliant. The facility is close to 5000 sq ft big with the state-of-art laboratory equipments and two class 10K clean rooms. It has been designed to meet the future plan of accreditation requirements of the USA Foundation for the Accreditation of cellular therapy (FACT) and the manufacturing process will adhere to cGTP (current Good Tissue Practice).
Stempeutics is committed to develop and deliver safe and effective stem cell therapy for the diseases where there is no cure. It is committed to helping patients by carrying out cutting edge research at its highest standards. Current focus is on bone marrow derived adult mesenchymal stem cells. Initial emphasis is on autologous cell therapies - where the bone marrow is aspirated from the patient, stem cells are isolated and upscaled and then injected back to the patient. So far the Bangalore facility has conducted pilot studies on 100 plus patients covering various diseases.
Stempeutics goal is to develop allogenic stem cell therapy in the near future so as to make this therapy more affordable, readily available off the shelf and also to be used in critical conditions. Stempeutics is the first company to employ a global hybrid model where by it offers both autologus and allogenic stem cell therapy for various diseases.
Speaking at the Press conference, Dr Ramdas Pai, Chancellor, Manipal University said "Stem Cell therapy is showing promising results for various diseases and it is currently used where the conventional therapies could not cure the disease. Keeping in mind the overall disease burden of various medical conditions and the potential for stem cell therapy globally, we are setting up our third lab at Kuala Lumpur Malaysia. Malaysia Lab will be operational in August 2008. With the expertise of the Clinicians at Kasturba Medical College at Manipal and Mangalore, we will stand to gain and realize the clinical value of stem cells".
Speaking at the Press conference Dr HS Ballal, Pro Chancellor, Manipal University said "We are happy on Stempeutics's commitment in developing Manipal as one of the Stem Cell Research and Therapy hubs. He said that Stempeutics should focus on CME programs in latest developments in Stem Cells research and also conduct formal hands on short term courses in Regenerative Medicine in collaboration with Manipal University. He also added that the stem cell research should be conducted in collaboration with various departments of the University with increased frequency of publications and patent portfolios".
Speaking at the Press conference Mr B.N. Manohar, President, Stempeutics Research said, "While the initial foray of Stempeutics is in bone marrow derived mesenchymal stem cells, Stempeutics is investing heavily on its R&D to bring out some innovative products (like tailor made progenitor cells) in the near future based on adult stem cells. It is also investing money on its long term goal of leveraging human embryonic stem cells for therapeutics purpose. Towards this goal Stempeutics will work closely with Manipal Assisted Reproduction Center in Kasturba Hospital for establishing human embryonic stem cells lines for advanced research. We want to become an undisputed leader in the Stem Cell area in this part of the world".
Speaking at Press conference Dr Satish Totey, Chief Scientific Officer, Stempeutics Research said, "Our mission is to ethically and scientifically explore the full potential of stem cells to transform medicine and offer new hope to millions of people. There will be continuous research for each disease so as to improve product development for effective therapy. Research will be conducted on effective cell number, route of transplantation etc. Further research will be carried out to develop lineage specific cells or precursor cells for more effective therapy. He said that Stempeutics will use the animal house at the University for doing Pre Clinical studies".
2022
